Heart:达比加群对导管消融房颤患者安全性与华法林相当

2013-07-29 高晓方 译 cmt

法国一项荟萃分析表明,在接受导管消融的房颤患者中,达比加群治疗者的血栓栓塞事件和大出血发生率与华法林相当,总体事件发生率低。论文于7月22日在线发表于《心脏》(Heart)。 研究者检索了Medline、Embase和Cochrane数据库,并纳入了在接受导管消融治疗的阵发性/持续性房颤患者中比较达比加群和华法林的对照试验。从纳入研究中提取围手术期全因死亡、血栓栓塞性事件和大出血等描述性和定

房颤患者抗凝治疗比例畸低

法国一项荟萃分析表明,在接受导管消融的房颤患者中,达比加群治疗者的血栓栓塞事件和大出血发生率与华法林相当,总体事件发生率低。论文于7月22日在线发表于《心脏》(Heart)。

研究者检索了Medline、Embase和Cochrane数据库,并纳入了在接受导管消融治疗的阵发性/持续性房颤患者中比较达比加群和华法林的对照试验。从纳入研究中提取围手术期全因死亡、血栓栓塞性事件和大出血等描述性和定量信息。

结果显示,共有包括4782例患者的14项研究符合纳入标准,其中达比加群和华法林治疗者分别为1823和2959例。未报告死亡。接受达比加群和华法林治疗的患者在血栓栓塞性事件(危险比[RR] 1.78;P=0.26)和大出血(RR 1.07;P=0.86)方面无显著差异。达比加群110 mg和150 mg 2次/日在大出血(P=0.25)和血栓栓塞(P=0.82)方面亦无显著差异。

Providência R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N, Narayanan K, Marijon E, Boveda S.Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.Heart. 2013 Jul 22.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2045111, encodeId=d49e2045111fe, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 26 09:56:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355782, encodeId=0d481355e8201, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399580, encodeId=890d1399580bb, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421571, encodeId=dcb214215e1b7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562179, encodeId=9c4f15621e96b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614221, encodeId=908f161422161, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2045111, encodeId=d49e2045111fe, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 26 09:56:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355782, encodeId=0d481355e8201, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399580, encodeId=890d1399580bb, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421571, encodeId=dcb214215e1b7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562179, encodeId=9c4f15621e96b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614221, encodeId=908f161422161, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
    2013-07-31 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=2045111, encodeId=d49e2045111fe, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 26 09:56:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355782, encodeId=0d481355e8201, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399580, encodeId=890d1399580bb, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421571, encodeId=dcb214215e1b7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562179, encodeId=9c4f15621e96b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614221, encodeId=908f161422161, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2045111, encodeId=d49e2045111fe, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 26 09:56:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355782, encodeId=0d481355e8201, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399580, encodeId=890d1399580bb, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421571, encodeId=dcb214215e1b7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562179, encodeId=9c4f15621e96b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614221, encodeId=908f161422161, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2045111, encodeId=d49e2045111fe, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 26 09:56:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355782, encodeId=0d481355e8201, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399580, encodeId=890d1399580bb, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421571, encodeId=dcb214215e1b7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562179, encodeId=9c4f15621e96b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614221, encodeId=908f161422161, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
    2013-07-31 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=2045111, encodeId=d49e2045111fe, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 26 09:56:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355782, encodeId=0d481355e8201, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399580, encodeId=890d1399580bb, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421571, encodeId=dcb214215e1b7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562179, encodeId=9c4f15621e96b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614221, encodeId=908f161422161, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]

相关资讯

PACE:房颤射频消融围手术期患者使用达比加群优于华法林

达比加群是新开发的一种直接抑制凝血酶的抗凝药物,其抗凝效应受饮食和合并用药的影响较小。另外,它在使用中无需监测凝血时间或调整剂量。RELY试验(长期抗凝治疗的随机化评估研究)在房颤患者减少卒中和出血并发症方面,达比加群非劣于华法林。为了评估这一结论是否也适用于进行房颤射频消融治疗的围手术期患者,已进行了两项研究。但两者均为非随机对照研究。为此TAKAMITSU NIN等设计了一项随机研究,试图评估

ASH 2012:达比加群大出血研究数据令人欣慰

       2012年第54届美国血液学学会(ASH)年会上公布新的数据显示,尽管实际上尚无特异性达比加群(Pradaxa,勃林格殷格翰公司)逆转剂,但达比加群大出血后的预后并不逊于华法林,实际上可能更好。          随着越来越多的指控勃林格殷格翰公司的药物导致出血死亡的报告浮出水面,

Circulation:基因多态性决定达比加群血药浓度及出血风险

RE-LY试验(Randomized Evaluation of Long-term Anticoagulation Therapy)结果显示达比加群酯110mg及150mg(每日两次)在预防非瓣膜性房颤患者卒中上优于华法林。两种剂型达比加群酯的大出血和轻微出血风险均较低。与维生素K拮抗剂不同,达比加群酯为固定剂量且不需抗凝监测。但达比加群活性代谢物血药浓度在不同个体之间存在较大的差异。遗传变异是

NEJM述评:达比加群引起的出血风险不高于华法林

达比加群VS华法林引发的颅内出血和胃肠道出血事件 美国食品和药品监督管理局(FDA)于2010年10月批准口服抗凝药达比加群([abigatran] Pradaxa,Boehringer Ingelheim)上市。此后的几年中,FDA不良事件报告系统(FAERS)收到许多使用该药导致严重和致死性出血事件的报告。达比加群是一种抗凝药,因此导致出血事件在意料之中,但报告发生率

CCI:达比加群并不能减少STEMI后行直接PCI术患者的梗死面积

HIRIZON-AMI研究是一项大型、前瞻性、随机的急性心肌梗死患者接受再血管化治疗和支架的预后研究。在这项研究中比较了在ST段抬高性心肌梗死患者在直接PCI术后,使用直接凝血酶原抑制剂达比加群与普通肝素加糖蛋白IIb/IIIa受体拮抗剂对全因死亡率和心血管死亡的影响。由于减少大出血事件方面的效应,达比加群组的死亡率较低。但对STEMI患者而言,心肌梗死面积是除了大出血之外的一项影响预后的重要因素

Stroke:亚洲房颤患者服用达比加群卒中预防效果一致且安全性更佳

一项发表在今年6月份美国《卒中》杂志上的、基于 RE-LY研究的最新亚组分析显示,泰毕全(达比加群酯)可为亚洲房颤患者和非亚洲房颤患者提供一致性的受益。与总体试验结果保持一致的是,泰毕全150 mg相较华法林可降低亚洲房颤患者的卒中和全身性栓塞(包括缺血性卒中)的发生风险。两种剂量方案的泰毕全(150mg和110mg)均可明显降低亚洲患者的出血性卒中发生风险。接受泰毕全治疗的亚洲患者的大出血